Courage under fire: what is the optimal approach to initial treatment of stable angina?
Nissen
Steven E
SE
Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA. nissens@ccf.org
D000787:Angina Pectoris / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014665:Vasodilator Agents; D009525:Niacin